Welcome
Hi, I’m Dr. Dennis Kwiatkowski, founder and principal consultant of Kwiatkowski Consulting. With a strong background in biomedical research, pharmaceutical strategy and commercial positioning, I have dedicated my career to providing expert knowledge and strategic advice. My mission is to help organizations tackle complex challenges, drive science- and data-driven decision-making, and make impactful contributions in the changing healthcare landscape.
Dr. Dennis Kwiatkowski
Biopharma Strategy Consulting
Extensive experience in strategic R&D support for 10+ European and US biotech & pharma companies.
Highlighted Projects
Due diligence & investment valuation: Execution of several due diligence projects for leading companies, including an international pharmaceutical company with a strong focus on rare diseases, a European subsidiary of a Japanese pharmaceutical group and an investment company specializing in biopharmaceutical financing strategies.
Portfolio prioritization: Supporting the strategic realignment of a biotech company with a focus on targeted alpha-radiation therapy, which was later acquired by a global pharmaceutical company.
Clinical development strategy: Evaluation and strategic consulting for a radiopharmaceutical company focusing on the clinical development of novel oncology therapies.
Scouting & Evaluation: Execution of several scouting and evaluation projects in the fields of oncology, rare diseases and immunology & inflammatory diseases. Analysis of over 3,000 assets for various biotech and pharmaceutical companies.
Indication & market analyses: Deep-dive analyses on indications in the field of immuno-oncology and hematologic malignancies to support business and development strategies for biopharmaceutical companies.
Target Validation: Evaluation of innovative target structures for immuno-oncology and RNA-based therapeutic approaches, including the analysis of screening platforms and small molecule approaches.
Technology review: Analysis and evaluation of novel platform technologies for an international pharmaceutical company to support long-term research strategy.
Biomedical Research
Research experience at leading institutions, including Charité Universitätsmedizin, Bayer Heathcare AG, Freie Universität Berlin, University of Greifswald and the Robert Koch Institute (RKI).
Important scientific contributions to the characterization of S. aureus proteins, the kinetics of CDK inhibitors, rhodopsins and G protein-coupled receptors (GPCRs) and developments in protein crystal structure analysis.
Selected publications & research highlights
- Elucidation of the structural and functional properties of S. aureus virulence factors, with relevance for new anti-infective strategies.
- Investigation of the kinetics of CDK inhibitors, with a focus on their therapeutic potential and molecular mechanisms of action.
- Analysis of the function and structure of rhodopsins, with relevance for optogenetic applications.
- Solving high-resolution protein crystal structures to improve the understanding of protein-ligand interactions.
- Research into GPCR signaling pathways to support drug development and targeted therapeutic approaches.
- Development of biochemical and structural biology methods to analyze protein-ligand interactions at the atomic level.
Ausbildung
Dr. rer. nat. (PhD)
Elucidation of the structure of rhodpsin and insight into the specificity of GPCRs
Zertifizierter Betriebswirt (IWW)
Business management fundamentals and specialization in the areas of strategic management, marketing management, strategic marketing planning, project management, international marketing and international management
Master of Science (M.Sc.)
Analysis of the binding kinetics of cyclin-dependent kinases
Bachelor of Science (B.Sc.)
Expression and characterization of virulence factors of S. Aureus